# US 2021/0332128 A1 · Humanized anti clever-1 antibodies and their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332128 A1
- Document ID: US20210332128A1
- Status: Published application
- Kind: A1
- Application number: 17/236,684
- Filed: 2021-04-21
- Published: 2021-10-28
- Earliest claimed: 2016-04-18
- Assignees: Faron Pharmaceuticals Oy
- Applicants: Faron Pharmaceuticals Oy
- Inventors: Mikael MAKSIMOW; Markku JALKANEN; Marita VAINIO
- Web page: https://patentgrep.com/patent/US20210332128A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to an agent and a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 recognizing an epitope of CLEVER-1, wherein the epitope is discontinuous and comprises the sequences: PFTVLVPSVSSFSSR and QEITVTFNQFTK. This invention relates also an agent capable of binding to an epitope of human CLEVER-1 for use in removing tumour or antigen induced immunosuppression. Further, the invention relates to a pharmaceutical composition comprising the agent capable of binding to human CLEVER-1 and an appropriate excipient.

## Claims

### Claim at position 1

1-2. (canceled)

### Claim 3

A method for treating cancer or chronic infection comprising administering a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 to a patient in need of such treatment, wherein said humanized antibody or single chain Fv or Fab fragment comprises the following sequences of complementarity determining regions (CDRs)
i) of the heavy chain
CDR 1:
(SEQ ID NO: 7)
TSGMGIG,
CDR 2:
(SEQ ID NO: 8)
HIWWDDDKRYNPALKS,
and
CDR 3:
(SEQ ID NO: 9)
HYGYDPYYAMDY;
and
ii) of the light chain
CDR 1:
(SEQ ID NO: 10)
TASSSVSSSYLH,
CDR 2:
(SEQ ID NO: 11)
RTSNLAS,
and
CDR 3:
(SEQ ID NO: 12)
HQYHRSPPT.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the humanized antibody or single chain FV or Fab fragment comprises constant regions of human IgG4 heavy chain and kappa light chain.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the humanized antibody or single chain Fv or Fab fragment comprises a human IgG heavy chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO 18 and SEQ ID NO: 20, and a human IgG light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 28 and SEQ ID NO: 30.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the humanized antibody or the single chain Fv or Fab fragment is capable of binding to human CLEVER-1 with a relative IC50<1.0 in comparison to the IC50 of monoclonal antibody 3-372 (DSM ACC2520 deposited at DSMZ-Deutsche Sammlung von Mikroorganismen and Zellkulturen GmbH on Aug. 21, 2001).

### Claim 7 (depends on 5)

The method according to claim 5, wherein the humanized antibody or the single chain Fv or Fab fragment is capable of binding to human CLEVER-1 with a relative IC50<0.8, <0.6 or <0.5 in comparison to the IC50 of monoclonal antibody 3-372.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the humanized antibody or the single chain Fv or Fab fragment is capable of binding to human CLEVER-1 with a relative IC50<0.5 in comparison to the IC50 of monoclonal antibody 3-372.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the combination of the human IgG heavy and light chain variable regions is selected from the group consisting of the following combinations:
SEQ ID NO: 14 and SEQ ID NO: 22.
SEQ ID NO: 16 and SEQ ID NO: 22.
SEQ ID NO: 16 and SEQ ID NO: 24
SEQ ID NO: 16 and SEQ ID NO: 26.
SEQ ID NO: 16 and SEQ ID NO: 28.
SEQ ID NO: 16 and SEQ ID NO: 30.
SEQ ID NO: 18 and SEQ ID NO: 22.
SEQ ID NO: 18 and SEQ ID NO: 24.
SEQ ID NO: 18 and SEQ ID NO: 28.
SEQ ID NO: 18 and SEQ ID NO: 30.
SEQ ID NO: 20 and SEQ ID NO: 24. and
SEQ ID NO: 20 and SEQ ID NO: 30.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the combination of human IgG heavy and light chain variable region sequence is selected from the group consisting of the following combinations: SEQ ID NO: 16 and SEQ ID NO: 30; SEQ ID NO: 18 and SEQ ID NO: 30; and SEQ ID NO: 20 and SEQ ID NO: 30.

### Claim 11 (depends on 4)

The method according to claim 4, wherein said antibody or single chain FV or Fab fragment comprises constant regions of human IgG4 heavy chain and kappa light chain with the mutations L248E and/or S241P.

### Claim 12 (depends on 3)

The method according to claim 3, wherein the method removes tumor or antigen induced immunosuppression by modulating M2 macrophages into M1 macrophages.

### Claim 13

A method for treating or preventing cancer by reducing the size of a malignant tumor; by reducing malignant tumour growth in an individual; and/or by inhibiting cancer cell transmigration and metastasis formation, comprising administering a humanized antibody or single chain Fv or Fab fragment capable of binding to human CLEVER-1 to a patient in need of such treatment, wherein said humanized antibody or single chain Fv or Fab fragment comprises the following sequences of complementarity determining regions (CDRs)
i) of the heavy chain
CDR 1:
(SEQ ID NO: 7)
TSGMGIG,
CDR 2:
(SEQ ID NO: 8)
HIWWDDDKRYNPALKS,
and
CDR 3:
(SEQ ID NO: 9)
HYGYDPYYAMDY;
and
ii) of the light chain
CDR 1:
(SEQ ID NO: 10)
TASSSVSSSYLH,
CDR 2:
(SEQ ID NO: 11)
RTSNLAS,
and
CDR 3:
(SEQ ID NO: 12)
HQYHRSPPT.

### Claim 14 (depends on 3)

The method according to claim 3, wherein the antibody or single chain Fv or Fab fragment binds to the epitope sequences:
(SEQ ID NO: 1)
PFTVLVPSVSSFSSR,
and
(SEQ ID NO: 2)
QEITVTFNQFTK
on human CLEVER-1.

### Claim 15 (depends on 3)

The method according to claim 3, wherein the antibody or single chain Fv or Fab fragment binds to one or more epitope sequences selected from the group consisting of
(SEQ ID NO: 3)
ATQTGRVFLQ,
(SEQ ID NO: 4)
DSLRDGRLIYLF,
(SEQ ID NO: 5)
SKGRILTMANQVL,
and
(SEQ ID NO: 6)
LCVYQKPGQAFCTCR
on human CLEVER-1.

### Claim 16 (depends on 3)

The method according to claim 3, wherein the antibody or single chain Fv or Fab fragment is administered intravenously, intraarticularly, intratumorally or subcutaneously.
